Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Burlington Stores Inc (BURL) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance

Burlington Stores IncTrade
Ginkgo Bioworks Holdings IncTrade

Price performance (Past 24H)

Key statistics

Burlington Stores Inc vs Ginkgo Bioworks Holdings Inc — how do they compare? Burlington Stores Inc trades at $333.33 (market cap $21.04B), while Ginkgo Bioworks Holdings Inc trades at $9.06 (market cap $590.53M). The key difference: Burlington Stores Inc is far larger — about 35.6× Ginkgo Bioworks Holdings Inc's market cap, and Burlington Stores Inc is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals.

BURLDNA
Market Cap
$21.04B$590.53M
Sector
Consumer CyclicalHealth
52-Week High
$347.82$16.14
52-Week Low
$242.43$5.48
Enterprise Value
$26.17B$627.78M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Burlington Stores Inc

Burlington Stores (BURL) trades at $327.59, showing minimal daily movement with a slight 0.04% decline. The stock maintains strong bullish technical signals with moving averages supporting upward momentum, though RSI levels suggest potential overbought conditions. Fundamentally, the company demonstrates robust performance with consistent earnings beats, including Q1 2026 EPS of $2.01 exceeding expectations of $1.80. Revenue growth continues with 2025 reaching $10.63 billion and projected increase to $11.9 billion in 2026.

Outlook remains positive with 94% analyst buy ratings and $364.40 consensus price target representing 11% upside. Key opportunities include margin expansion and store productivity improvements, while risks involve competitive retail pressures and inventory management challenges. The company's strong cash flow generation and debt-to-asset ratio of 19.5% provide financial stability for continued growth initiatives.

Ginkgo Bioworks Holdings Inc

DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.

The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.

Returns comparison

Trailing returns across standard periods

About Burlington Stores Inc

Burlington is a leading off-price retailer in the US, offering branded apparel, footwear, and home goods at significant discounts. It operates hundreds of stores focused on delivering high-quality products at great value.

Read more on BURL

About Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.

Read more on DNA